Paul Tudor Jones's SRPT Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 68.83 M shares of Sarepta Therapeutics, Inc. (SRPT) worth $63.35 M, representing 0.11% of the portfolio. First purchased in 2015-Q3, this long-term strategic position has been held for 41 quarters.
Based on 13F filings since 2013, Paul Tudor Jones has maintained a long-term strategic position in SRPT, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2025, adding 68.78 M shares. Largest reduction occurred in Q1 2017, reducing 135,004 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Sarepta Therapeutics (SRPT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Sarepta Therapeutics (SRPT) Trades by Paul Tudor Jones
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2015 | +24,042 | New Buy | 24,042 | $32.11 |
| Q4 2015 | -24,042 | Sold Out | 24,042 | $0.00 |
| Q3 2016 | +215,933 | New Buy | 215,933 | $61.41 |
| Q4 2016 | -215,933 | Sold Out | 215,933 | $0.00 |
| Q1 2017 | +80,929 | New Buy | 80,929 | $29.59 |
| Q2 2017 | -53,412 | Reduce 66.00% | 27,517 | $33.72 |
| Q3 2017 | -27,517 | Sold Out | 27,517 | $0.00 |
| Q2 2018 | +40,761 | New Buy | 40,761 | $132.19 |
| Q3 2018 | -40,761 | Sold Out | 40,761 | $0.00 |
| Q2 2020 | +14,034 | New Buy | 14,034 | $160.32 |
| Q3 2020 | -14,034 | Sold Out | 14,034 | $0.00 |
| Q4 2020 | +2,812 | New Buy | 2,812 | $170.34 |
| Q1 2021 | +3,672 | Add 130.58% | 6,484 | $74.49 |
| Q2 2021 | +50,173 | Add 773.80% | 56,657 | $77.75 |
| Q3 2021 | -56,657 | Sold Out | 56,657 | $0.00 |
| Q4 2021 | +2,701 | New Buy | 2,701 | $89.97 |
| Q1 2022 | +1,682 | Add 62.27% | 4,383 | $78.03 |
| Q2 2022 | -4,383 | Sold Out | 4,383 | $0.00 |
| Q3 2022 | +35,248 | New Buy | 35,248 | $110.53 |
| Q4 2022 | -4,836 | Reduce 13.72% | 30,412 | $0.13 |
| Q1 2023 | -15,851 | Reduce 52.12% | 14,561 | $0.14 |
| Q2 2023 | -14,561 | Sold Out | 14,561 | $0.00 |
| Q4 2023 | +62,800 | New Buy | 62,800 | $96.43 |
| Q1 2024 | -62,800 | Sold Out | 62,800 | $0.00 |
| Q2 2025 | +50,851 | New Buy | 50,851 | $17.10 |
| Q3 2025 | +68.78 M | Add 135261.75% | 68.83 M | $0.92 |
Paul Tudor Jones's Sarepta Therapeutics Investment FAQs
Paul Tudor Jones first purchased Sarepta Therapeutics, Inc. (SRPT) in Q3 2015, acquiring 24,042 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Sarepta Therapeutics, Inc. (SRPT) for 41 quarters since Q3 2015. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones's largest addition to Sarepta Therapeutics, Inc. (SRPT) was in Q3 2025, adding 68,832,803 shares worth $63.35 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 68,832,803 shares of Sarepta Therapeutics, Inc. (SRPT), valued at approximately $63.35 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Sarepta Therapeutics, Inc. (SRPT) represents approximately 0.11% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones's peak holding in Sarepta Therapeutics, Inc. (SRPT) was 68,832,803 shares, as reported at the end of Q3 2025. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.